Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review.

Autor: Mohammadnezhad G; Student Research Committee, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Azadmehr B; Student Research Committee, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Mirheidari M; Student Research Committee, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Yousefi N; Department of Pharmacoeconomics and Pharma Management, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. n.yousefi@sbmu.ac.ir.
Jazyk: angličtina
Zdroj: Cost effectiveness and resource allocation : C/E [Cost Eff Resour Alloc] 2022 Dec 01; Vol. 20 (1), pp. 62. Date of Electronic Publication: 2022 Dec 01.
DOI: 10.1186/s12962-022-00396-7
Abstrakt: Objectives: This study was aimed to systematically review published economic studies to determine whether dapagliflozin, a sodium-glucose co-transporter inhibitor, plus standard care therapy (SCT) is cost-effective in heart failure with reduced ejection fraction (HFrEF).
Method: We searched relevant keywords in PubMed, Scopus, Web of science, and Google Scholar to find related articles. Costs, QALYs, ICERs were extracted from eligible studies.
Results: Ten studies finally included in the systematic review. The results of quality assessment of the study showed that a reasonable quality of all studies. Incremental QALYs were in favor of dapagliflozin plus SCT treatment regimen. In all the studies, the incremental costs per QALY was below the willingness-to-pay (WTP) threshold with the exception of one study in United Kingdom which the ICER and WTP were $83,650 and $50,000. All the studies determined the National Health Care perspective. The highest and lowest ICERs were $83,650 and $1991 per QALY in United Kingdom and Thailand, respectively.
Conclusion: Results of cost-effectiveness analyses showed that adjunct dapagliflozin plus SCT is cost-effective compared to SCT alone despite the additional costs of the drug. Finally it can be concluded that dapagliflozin is a worldwide cost-effective as an adjunct medicine in HFrEF management.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje